首页 | 本学科首页   官方微博 | 高级检索  
     

肝素酶在人非小细胞肺癌组织中的表达研究
引用本文:于敏,董昕,李姝玉,侯萍,龙飞,Iris Pecker,王恩华,邱雪杉. 肝素酶在人非小细胞肺癌组织中的表达研究[J]. 中国肺癌杂志, 2004, 7(1): 16-21
作者姓名:于敏  董昕  李姝玉  侯萍  龙飞  Iris Pecker  王恩华  邱雪杉
作者单位:1. 110001,沈阳,中国医科大学基础医学院病理学教研室
2. 以色列,Insight Strategy & Marketing Ltd.
基金项目:国家自然科学基金项目 (No .30 1 70 4 0 9),辽宁省教育厅科研基金项目 (No.2 0 1 2 2 1 78)资助~~
摘    要:目的 探讨肝素酶(heparanase,Hpa)在人非小细胞肺癌组织中的表达及其与患者临床病理特征之间的关系,明确其对肺癌患者预后的意义。方法 采用免疫组织化学染色(S-P法)和Western blot检测122例人非小细胞肺癌石蜡包埋组织和38例新鲜肺癌组织及相应癌旁正常肺组织中肝素酶的表达情况,并用x^2检验、Cox比例风险模型和生存曲线等方法分析肝素酶在肺癌组织中的表达意义。结果 肝素酶主要表达在癌细胞膜和/或细胞浆中。免疫组织化学结果表明:在122例非小细胞肺癌组织中有96例(78.7%)呈肝素酶阳性表达,而癌旁正常支气管和肺泡上皮中无阳性表达。Westcrn blot结果亦证实肝素酶在肺癌叶的表达较癌旁正常肺组织明显增高(P=0.043)。x^2检验显示肝素酶表达与肺癌的临床分期(P=0.025)、淋巴结转移(P=0.002)和血管浸润(P=0.0003)有密切关系。生存曲线分析表明肝素酶阳性表达组患者的5年生存率明显低于阴性组(P=0.0006)。但多因素分析结果显示仅肺癌的分期、淋巴结转移和血管浸润可作为影响患者预后的风险因素。结论 肝素酶在人肺癌组织中的表达较正常肺组织明显上调,并与肺癌的临床分期、侵袭、转移和患者的预后相关,但不能作为患者预后评估的独立指标。

关 键 词:肝素酶 非小细胞肺癌 预后 病理特征 免疫组织化学染色 检测
修稿时间:2003-07-21

Expression of heparanase in human non-small cell lung cancer
YU Min,DONG Xin,LI Shuyu,HOU Ping,LONG Fei,Iris Pecker,WANG Enhua,QIU Xueshan. Expression of heparanase in human non-small cell lung cancer[J]. Chinese journal of lung cancer, 2004, 7(1): 16-21
Authors:YU Min  DONG Xin  LI Shuyu  HOU Ping  LONG Fei  Iris Pecker  WANG Enhua  QIU Xueshan
Affiliation:YU Min,DONG Xin,LI Shuyu,HOU Ping,LONG Fei,Iris Pecker,WANG Enhua,QIU Xueshan. Department of Pathology,China Medical University,Shenyang,Liaoning 110001,P.R.China
Abstract:Objective To study the relationship between human heparanase expression and biological factors regarding invasion, metastasis and prognosis of human non small cell lung cancer (NSCLC). Methods The expression of heparanase was assessed in 122 paraffin embedded specimens and 38 freshly taken tissues by immunohistochemical staining and Western blot. The relationship between heparanase expression and the clinicopathological factors was analyzed by Chi square test, multivariate analysis and Kaplan Meier method. Results In the immunoreactive cells, staining was mainly located in cytoplasma and membrane. Human heparanase was highly expressed in lung cancer tissues (78.7%, 96/122) while negative in epithelia of normal lung tissues. The level of heparanase was remarkably higher in NSCLC than that in normal tissues ( P = 0.043 ). Expression of heparanase significantly correlated with TNM stage ( P =0.025), lymphatic metastasis ( P =0.002) and vascular invasion ( P =0.000 3). The patients with positive heparanase expression had a significantly shorter survival than those with negative heparanase expression ( P =0.000 6). In multivariate analysis, only p TNM stage, lymphatic metastasis and vascular invasion could be considered as prognostic factors. Conclusion Heparanase might play an important role in the development, invasion and metastasis of NSCLC. It is indicated that patients with positive heparanase expression would have a greater chance of metastasis and a poorer prognosis. However, heparanase expression is not an independent prognostic factor.
Keywords:Non small cell lung cancer Heparanase Metastasis Prognosis
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号